{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T05:50:53Z","timestamp":1776577853219,"version":"3.51.2"},"reference-count":108,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001780","name":"RMIT University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.drudis.2019.11.008","type":"journal-article","created":{"date-parts":[[2019,11,22]],"date-time":"2019-11-22T12:04:47Z","timestamp":1574424287000},"page":"367-379","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["New generation drugs for treatment of multiple myeloma"],"prefix":"10.1016","volume":"25","author":[{"given":"Fehaid","family":"Alanazi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faith A.A.","family":"Kwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Genia","family":"Burchall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denise E.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.drudis.2019.11.008_bib0005","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1080\/09674845.2013.11669945","article-title":"Multiple myeloma: the bone marrow microenvironment and its relation to treatment","volume":"70","author":"Andrews","year":"2013","journal-title":"Br. J. Biomed. Sci."},{"key":"10.1016\/j.drudis.2019.11.008_bib0010","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/nyas.13038","article-title":"Multiple myeloma in the marrow: pathogenesis and treatments","volume":"1364","author":"Fairfield","year":"2016","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"9983","key":"10.1016\/j.drudis.2019.11.008_bib0015","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/S0140-6736(14)60493-1","article-title":"Multiple myeloma","volume":"385","author":"Rollig","year":"2015","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.drudis.2019.11.008_bib0020","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood.V100.4.1417.h81602001417_1417_1424","article-title":"Genomic abnormalities in monoclonal gammopathy of undetermined significance","volume":"100","author":"Fonseca","year":"2002","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.drudis.2019.11.008_bib0025","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s12185-013-1291-2","article-title":"Molecular pathogenesis of multiple myeloma: basic and clinical updates","volume":"97","author":"Chesi","year":"2013","journal-title":"Int. J. Hematol."},{"issue":"7","key":"10.1016\/j.drudis.2019.11.008_bib0030","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1038\/leu.2009.26","article-title":"Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial","volume":"23","author":"Reeder","year":"2009","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.drudis.2019.11.008_bib0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bcp.2015.04.008","article-title":"Proteasome inhibitors","volume":"96","author":"Teicher","year":"2015","journal-title":"Biochem. Pharmacol."},{"issue":"5","key":"10.1016\/j.drudis.2019.11.008_bib0040","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1182\/blood-2009-01-199604","article-title":"Bortezomib induces canonical nuclear factor-\u03baB activation in multiple myeloma cells","volume":"114","author":"Hideshima","year":"2009","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.drudis.2019.11.008_bib0045","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1182\/blood-2010-02-268862","article-title":"Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma","volume":"116","author":"Richardson","year":"2010","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.drudis.2019.11.008_bib0050","doi-asserted-by":"crossref","first-page":"6379","DOI":"10.1158\/0008-5472.CAN-06-0605","article-title":"Comparative selectivity and specificity of the proteasome inhibitors BzLLLCOCHO, PS-341, and MG-132","volume":"66","author":"Crawford","year":"2006","journal-title":"Cancer Res."},{"issue":"9","key":"10.1016\/j.drudis.2019.11.008_bib0055","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1038\/sj.leu.2404806","article-title":"Bortezomib inhibits human osteoclastogenesis","volume":"21","author":"von Metzler","year":"2007","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.drudis.2019.11.008_bib0060","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1158\/1078-0432.CCR-10-1950","article-title":"Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events","volume":"17","author":"Arastu-Kapur","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.drudis.2019.11.008_bib0065","first-page":"167","article-title":"Safety Of proteasome inhibitors for treatment of multiple myeloma","volume":"16","author":"Schlafer","year":"2017","journal-title":"Expert Opin. Drug Saf."},{"issue":"5","key":"10.1016\/j.drudis.2019.11.008_bib0070","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2019-000570","article-title":"European Medicines Agency review of ixazomib (Ninlaro) for the treatment of adult patients with multiple myeloma who have received at least one prior therapy","volume":"4","author":"Tzogani","year":"2019","journal-title":"ESMO Open"},{"issue":"17","key":"10.1016\/j.drudis.2019.11.008_bib0075","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1080\/14656566.2018.1528229","article-title":"Ixazomib for the treatment of multiple myeloma","volume":"19","author":"Richardson","year":"2018","journal-title":"Expert Opin. Pharmacother."},{"issue":"4","key":"10.1016\/j.drudis.2019.11.008_bib0080","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/bjh.14733","article-title":"Management of adverse events associated with ixazomib plus lenalidomide\/dexamethasone in relapsed\/refractory multiple myeloma","volume":"178","author":"Kumar","year":"2017","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.drudis.2019.11.008_bib0085","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/leu.2009.236","article-title":"Mechanism 0f action of immunomodulatory drugs (IMiDS) in multiple myeloma","volume":"24","author":"Quach","year":"2010","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.drudis.2019.11.008_bib0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/toxsci\/kfr088","article-title":"Thalidomide: the tragedy of birth defects and the effective treatment of disease","volume":"122","author":"Kim","year":"2011","journal-title":"Toxicol. Sci."},{"issue":"1","key":"10.1016\/j.drudis.2019.11.008_bib0095","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3109\/08923973.2012.726627","article-title":"Therapeutic options for patients with angioedema due to C1-inhibitor deficiencies: from pathophysiology to the clinic","volume":"35","author":"Castelli","year":"2013","journal-title":"Immunopharmacol. Immunotoxicol."},{"issue":"19","key":"10.1016\/j.drudis.2019.11.008_bib0100","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1056\/NEJMoa1112704","article-title":"Continuous lenalidomide treatment for newly diagnosed multiple myeloma","volume":"366","author":"Palumbo","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.drudis.2019.11.008_bib0105","doi-asserted-by":"crossref","first-page":"5291","DOI":"10.1182\/blood-2007-12-130120","article-title":"Lenalidomide Induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia","volume":"111","author":"Ferrajoli","year":"2008","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.drudis.2019.11.008_bib0110","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1182\/blood-2015-07-567958","article-title":"The novel mechanism of lenalidomide activity","volume":"126","author":"Fink","year":"2015","journal-title":"Blood"},{"issue":"6168","key":"10.1016\/j.drudis.2019.11.008_bib0115","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1244851","article-title":"Lenalidomide causes selective degradation of Ikzf1 and Ikzf3 in multiple myeloma cells","volume":"343","author":"Kronke","year":"2014","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.drudis.2019.11.008_bib0120","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s40273-017-0581-6","article-title":"Pomalidomide with dexamethasone for treating relapsed and refractory multiple myeloma previously treated with lenalidomide and bortezomib: an evidence review group perspective of an nice single technology appraisal","volume":"36","author":"B\u00fcy\u00fckkaramikli","year":"2018","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.drudis.2019.11.008_bib0125","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2013.38","article-title":"Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma","volume":"3","author":"Chanan-Khan","year":"2013","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.drudis.2019.11.008_bib0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0079-6123(10)82001-1","article-title":"Glucocorticoid-induced apoptosis of healthy and malignant lymphocytes","volume":"182","author":"Smith","year":"2010","journal-title":"Prog. Brain Res."},{"issue":"6","key":"10.1016\/j.drudis.2019.11.008_bib0135","first-page":"1681","article-title":"Mechanisms Of glucocorticoid-mediated apoptosis in hematological malignancies","volume":"8","author":"Greenstein","year":"2002","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.drudis.2019.11.008_bib0140","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.3390\/ijms18071414","article-title":"Histone deacetylase inhibitors as anticancer drugs","volume":"18","author":"Eckschlager","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.drudis.2019.11.008_bib0145","doi-asserted-by":"crossref","first-page":"475","DOI":"10.3390\/cancers11040475","article-title":"HDAC inhibitors exert anti-myeloma effects through multiple modes of action","volume":"11","author":"Imai","year":"2019","journal-title":"Cancers"},{"issue":"9","key":"10.1016\/j.drudis.2019.11.008_bib0150","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-018-0119-y","article-title":"The biological significance of histone modifiers in multiple myeloma: clinical applications","volume":"8","author":"Ohguchi","year":"2018","journal-title":"Blood Cancer J."},{"issue":"11","key":"10.1016\/j.drudis.2019.11.008_bib0155","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.4161\/15592294.2014.983367","article-title":"Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma","volume":"9","author":"Mithraprabhu","year":"2014","journal-title":"Epigenetics"},{"issue":"12","key":"10.1016\/j.drudis.2019.11.008_bib0160","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1002\/phar.1671","article-title":"Role of histone deacetylase inhibitors in relapsed refractory multiple myeloma: a focus on vorinostat and panobinostat","volume":"35","author":"Afifi","year":"2015","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.drudis.2019.11.008_bib0165","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.2147\/OTT.S30773","article-title":"Profile of panobinostat and its potential for treatment in solid tumors: an update","volume":"6","author":"Anne","year":"2013","journal-title":"Onco Targets Ther."},{"issue":"6","key":"10.1016\/j.drudis.2019.11.008_bib0170","doi-asserted-by":"crossref","first-page":"731","DOI":"10.3390\/nu10060731","article-title":"Targeting histone deacetylases with natural and synthetic agents: an emerging anticancer strategy","volume":"10","author":"Singh","year":"2018","journal-title":"Nutrients"},{"issue":"5","key":"10.1016\/j.drudis.2019.11.008_bib0175","first-page":"296","article-title":"Panobinostat (Farydak): a novel option for the treatment of relapsed or relapsed and refractory multiple myeloma","volume":"41","author":"Moore","year":"2016","journal-title":"P. T."},{"issue":"3","key":"10.1016\/j.drudis.2019.11.008_bib0180","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1152\/physrev.00035.2007","article-title":"Evolution and function of the ADP ribosyl cyclase\/Cd38 gene family in physiology and pathology","volume":"88","author":"Malavasi","year":"2008","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.drudis.2019.11.008_bib0185","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3389\/fimmu.2017.00305","article-title":"Roles and modalities of ectonucleotidases in remodeling the multiple myeloma niche","volume":"8","author":"Chillemi","year":"2017","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.drudis.2019.11.008_bib0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0145-2126(00)00093-X","article-title":"Human Cd38: a (R)evolutionary story of enzymes and receptors","volume":"25","author":"Deaglio","year":"2001","journal-title":"Leuk. Res."},{"issue":"1","key":"10.1016\/j.drudis.2019.11.008_bib0195","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood-2017-06-740944","article-title":"CD38 antibodies in multiple myeloma: back to the future","volume":"131","author":"van de Donk","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.drudis.2019.11.008_bib0200","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/blood-2016-03-705210","article-title":"Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple Myeloma","volume":"128","author":"Usmani","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.drudis.2019.11.008_bib0205","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13045-016-0283-0","article-title":"Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma","volume":"9","author":"Sanchez","year":"2016","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.drudis.2019.11.008_bib0210","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/imr.12389","article-title":"Monoclonal antibodies targeting Cd38 in hematological malignancies and beyond","volume":"270","author":"van de Donk","year":"2016","journal-title":"Immunol. Rev."},{"issue":"11","key":"10.1016\/j.drudis.2019.11.008_bib0215","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1002\/ajh.24883","article-title":"Efficacy Of daratumumab-based therapies in patients with relapsed, refractory multiple myeloma treated outside of clinical trials","volume":"92","author":"Lakshman","year":"2017","journal-title":"Am. J. Hematol."},{"issue":"10027","key":"10.1016\/j.drudis.2019.11.008_bib0220","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(15)01120-4","article-title":"Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (Sirius): an open-label, randomised, phase 2 trial","volume":"387","author":"Lonial","year":"2016","journal-title":"Lancet"},{"issue":"6 Pt 2","key":"10.1016\/j.drudis.2019.11.008_bib0225","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1111\/trf.13069","article-title":"Resolving The daratumumab interference with blood compatibility testing","volume":"55","author":"Chapuy","year":"2015","journal-title":"Transfusion"},{"issue":"5","key":"10.1016\/j.drudis.2019.11.008_bib0230","first-page":"451","article-title":"Novel combination treatments in multiple myeloma","volume":"30","author":"Nooka","year":"2016","journal-title":"Oncology"},{"issue":"21","key":"10.1016\/j.drudis.2019.11.008_bib0235","article-title":"Initial phase 3 results of the first (Frontline Investigation Of Lenalidomide + Dexamethasone Versus Standard Thalidomide) trial (MM-020\/IFM 07 01) in newly diagnosed multiple myeloma (NDMM) patients (Pts) ineligible for stem cell transplantation (SCT)","volume":"122","author":"Dimopoulos","year":"2013","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.drudis.2019.11.008_bib0240","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"Suppl 1","key":"10.1016\/j.drudis.2019.11.008_bib0245","first-page":"5","article-title":"Relapsed or relapsed\/refractory multiple myeloma","volume":"4","author":"Kurtin","year":"2013","journal-title":"J. Adv. Pract. Oncol."},{"issue":"1","key":"10.1016\/j.drudis.2019.11.008_bib0250","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/leu.2011.196","article-title":"Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study","volume":"26","author":"Kumar","year":"2012","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.drudis.2019.11.008_bib0255","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0301-472X(01)00788-3","article-title":"Leukemic B cells clonally identical to myeloma plasma cells are myelomagenic in NOD\/SCID mice","volume":"30","author":"Pilarski","year":"2002","journal-title":"Exp. Hematol."},{"issue":"1","key":"10.1016\/j.drudis.2019.11.008_bib0260","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1158\/0008-5472.CAN-07-3096","article-title":"Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance","volume":"68","author":"Matsui","year":"2008","journal-title":"Cancer Res."},{"issue":"21","key":"10.1016\/j.drudis.2019.11.008_bib0265","doi-asserted-by":"crossref","first-page":"7599","DOI":"10.1158\/1078-0432.CCR-05-0523","article-title":"The phenotypic plasticity of myeloma plasma cells as expressed by dedifferentiation into an immature, resilient, and apoptosis-resistant phenotype","volume":"11","author":"Yaccoby","year":"2005","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.drudis.2019.11.008_bib0270","doi-asserted-by":"crossref","first-page":"876","DOI":"10.3892\/ijo.2012.1545","article-title":"Multiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomide","volume":"41","author":"Kawano","year":"2012","journal-title":"Int. J. Oncol."},{"issue":"6","key":"10.1016\/j.drudis.2019.11.008_bib0275","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1182\/blood-2003-09-3064","article-title":"Characterization of clonogenic multiple myeloma cells","volume":"103","author":"Matsui","year":"2004","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.drudis.2019.11.008_bib0280","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1182\/blood.V88.2.622.bloodjournal882622","article-title":"Tumor-specific aneuploidy not detected in Cd19+ B-lymphoid cells from myeloma patients in a multidimensional flow cytometric analysis","volume":"88","author":"McSweeney","year":"1996","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.drudis.2019.11.008_bib0285","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1182\/blood-2013-07-517276","article-title":"A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed\/refractory myeloma","volume":"123","author":"Richardson","year":"2014","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.drudis.2019.11.008_bib0290","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.drudis.2019.11.008_bib0295","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.drudis.2019.11.008_bib0300","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1080\/10428194.2017.1298755","article-title":"Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup","volume":"58","author":"Ludwig","year":"2017","journal-title":"Leuk. Lymphoma"},{"issue":"11","key":"10.1016\/j.drudis.2019.11.008_bib0305","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","article-title":"Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (Mm-003): a randomised, open-label, phase 3 trial","volume":"14","author":"Miguel","year":"2013","journal-title":"Lancet Oncol."},{"issue":"30","key":"10.1016\/j.drudis.2019.11.008_bib0310","doi-asserted-by":"crossref","first-page":"5008","DOI":"10.1200\/JCO.2009.23.6802","article-title":"Pomalidomide (Cc4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma","volume":"27","author":"Lacy","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.drudis.2019.11.008_bib0315","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1634\/theoncologist.2017-0301","article-title":"EMA review of panobinostat (Farydak) for the treatment of adult patients with relapsed and\/or refractory multiple myeloma","volume":"23","author":"Tzogani","year":"2018","journal-title":"Oncologist"},{"issue":"14","key":"10.1016\/j.drudis.2019.11.008_bib0320","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1182\/blood-2013-01-481325","article-title":"PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma","volume":"122","author":"Richardson","year":"2013","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.drudis.2019.11.008_bib0325","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1182\/blood-2015-09-665018","article-title":"Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment","volume":"127","author":"Richardson","year":"2016","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.drudis.2019.11.008_bib0330","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral Ixazomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"10.1016\/j.drudis.2019.11.008_bib0335","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.drudis.2019.11.008_bib0340","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1182\/blood-2017-05-785246","article-title":"Daratumumab plus pomalidomide and dexamethasone in relapsed and\/or refractory multiple myeloma","volume":"130","author":"Chari","year":"2017","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.drudis.2019.11.008_bib0345","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.1158\/1078-0432.CCR-14-1813","article-title":"Preclinical evidence for the therapeutic potential of Cd38-targeted immuno-chemotherapy in multiple myeloma patients refractory to lenalidomide and bortezomib","volume":"21","author":"Nijhof","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.drudis.2019.11.008_bib0350","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.apsb.2018.03.001","article-title":"The application of CAR-T cell therapy in hematological malignancies: advantages and challenges","volume":"8","author":"Zhao","year":"2018","journal-title":"Acta Pharm. Sin. B"},{"issue":"3","key":"10.1016\/j.drudis.2019.11.008_bib0355","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/phar.1900","article-title":"Chimeric antigen receptor T cells in hematologic malignancies","volume":"37","author":"Shank","year":"2017","journal-title":"Pharmacotherapy"},{"issue":"2","key":"10.1016\/j.drudis.2019.11.008_bib0360","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1309\/617DWB5GNFWXHW4L","article-title":"CD138 (syndecan-1), a plasma cell marker immunohistochemical profile in hematopoietic and nonhematopoietic neoplasms","volume":"121","author":"O\u2019Connell","year":"2004","journal-title":"Am. J. Clin. Pathol."},{"issue":"1","key":"10.1016\/j.drudis.2019.11.008_bib0365","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jocit.2014.11.001","article-title":"CD138-directed adoptive immunotherapy of chimeric antigen receptor (CAR)-modified T cells for multiple myeloma","volume":"2","author":"Guo","year":"2016","journal-title":"J. Cell. Immunother."},{"issue":"13","key":"10.1016\/j.drudis.2019.11.008_bib0370","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1182\/blood-2016-04-711903","article-title":"T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma","volume":"128","author":"Ali","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2019.11.008_bib0375","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.critrevonc.2016.07.006","article-title":"Revisiting IL-6 antagonism in multiple myeloma","volume":"105","author":"Matthes","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"1","key":"10.1016\/j.drudis.2019.11.008_bib0380","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-018-0681-6","article-title":"A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma","volume":"11","author":"Zhao","year":"2018","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.drudis.2019.11.008_bib0385","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12885-016-3032-4","article-title":"Incidence of Venous Thromboembolism in cancer patients treated with Cisplatin based chemotherapy - a cohort study","volume":"17","author":"Zahir","year":"2017","journal-title":"BMC Cancer"},{"issue":"11","key":"10.1016\/j.drudis.2019.11.008_bib0390","first-page":"785","article-title":"Thrombosis and platelets: an update","volume":"38","author":"Koupenova","year":"2017","journal-title":"Eur. Heart J."},{"issue":"4","key":"10.1016\/j.drudis.2019.11.008_bib0395","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1161\/ATVBAHA.112.246181","article-title":"A2 adenosine receptors and vascular pathologies","volume":"32","author":"Johnston-Cox","year":"2012","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"1","key":"10.1016\/j.drudis.2019.11.008_bib0400","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood-2009-12-257519","article-title":"High incidence of arterial thrombosis in young patients treated for multiple myeloma: results of a prospective cohort study","volume":"116","author":"Libourel","year":"2010","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.drudis.2019.11.008_bib0405","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1172\/JCI60229","article-title":"New insights into the mechanisms of venous thrombosis","volume":"122","author":"Mackman","year":"2012","journal-title":"J. Clin. Invest."},{"issue":"6","key":"10.1016\/j.drudis.2019.11.008_bib0410","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1001\/archinte.160.6.809","article-title":"Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study","volume":"160","author":"Heit","year":"2000","journal-title":"Arch. Intern. Med."},{"issue":"3","key":"10.1016\/j.drudis.2019.11.008_bib0415","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1055\/s-0034-1370793","article-title":"Venous thromboembolism in multiple myeloma","volume":"40","author":"De Stefano","year":"2014","journal-title":"Semin. Thromb. Hemost."},{"issue":"7","key":"10.1016\/j.drudis.2019.11.008_bib0420","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1001\/jamaoncol.2016.3350","article-title":"Cardiovascular and thrombotic complications of novel multiple myeloma therapies: a review","volume":"3","author":"Li","year":"2017","journal-title":"JAMA Oncol."},{"issue":"11","key":"10.1016\/j.drudis.2019.11.008_bib0425","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.3324\/haematol.2013.089334","article-title":"Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies","volume":"98","author":"Siegel","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.drudis.2019.11.008_bib0430","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2014.93","article-title":"Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomib","volume":"5","author":"Atrash","year":"2015","journal-title":"Blood Cancer J."},{"issue":"1","key":"10.1016\/j.drudis.2019.11.008_bib0435","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1586\/ehm.12.62","article-title":"Immunomodulatory drugs in multiple myeloma","volume":"6","author":"Andhavarapu","year":"2013","journal-title":"Expert Rev. Hematol."},{"issue":"22","key":"10.1016\/j.drudis.2019.11.008_bib0440","doi-asserted-by":"crossref","first-page":"4726","DOI":"10.1182\/blood.V128.22.4726.4726","article-title":"Risk of venous thromboembolism in multiple myeloma: identification of risk factor","volume":"128","author":"Sanfilippo","year":"2016","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.drudis.2019.11.008_bib0445","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1157\/13116658","article-title":"Cardiovascular risk factors. Insights from Framingham Heart Study","volume":"61","author":"O\u2019Donnell","year":"2008","journal-title":"Rev. Esp. Cardiol."},{"issue":"21","key":"10.1016\/j.drudis.2019.11.008_bib0450","doi-asserted-by":"crossref","first-page":"5073","DOI":"10.1182\/blood.V118.21.5073.5073","article-title":"Retrospective analysis of thrombocytopenia in relapsed multiple myeloma patients","volume":"118","author":"Sousa","year":"2011","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.drudis.2019.11.008_bib0455","first-page":"127","article-title":"Hemostatic abnormalities in multiple myeloma patients","volume":"19","author":"Gogia","year":"2018","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"12","key":"10.1016\/j.drudis.2019.11.008_bib0460","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.1182\/blood-2005-03-1173","article-title":"Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma","volume":"106","author":"Lonial","year":"2005","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.drudis.2019.11.008_bib0465","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.1172\/JCI75247","article-title":"Proteasome function is required for platelet production","volume":"124","author":"Shi","year":"2014","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.drudis.2019.11.008_bib0470","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3816\/CLM.2009.n.035","article-title":"Melphalan, prednisone, and lenalidomide for newly diagnosed myeloma: kinetics of neutropenia and thrombocytopenia and time-to-event results","volume":"9","author":"Palumbo","year":"2009","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"8","key":"10.1016\/j.drudis.2019.11.008_bib0475","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.drudis.2019.11.008_bib0480","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/rth2.12009","article-title":"Treatment of refractory delayed onset heparin-induced thrombocytopenia after thoracic endovascular aortic repair with intravenous immunoglobulin (IVIG)","volume":"1","author":"Doucette","year":"2017","journal-title":"Res. Pract. Thromb. Haemost."},{"issue":"4","key":"10.1016\/j.drudis.2019.11.008_bib0485","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1177\/1076029615613158","article-title":"Venous thromboembolism in patients with thrombocytopenia: risk factors, treatment, and outcome","volume":"23","author":"Baelum","year":"2017","journal-title":"Clin. Appl. Thromb. Hemost."},{"issue":"22","key":"10.1016\/j.drudis.2019.11.008_bib0490","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.531.531","article-title":"Treatment of venous thromboembolism in patients with hematological malignancies and severe thrombocytopenia: a retrospective cohort analysis","volume":"128","author":"Houghton","year":"2016","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.drudis.2019.11.008_bib0495","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1586\/14737140.7.3.307","article-title":"Thrombosis in multiple myeloma","volume":"7","author":"Zangari","year":"2007","journal-title":"Expert Rev. Anticancer Ther."},{"issue":"3","key":"10.1016\/j.drudis.2019.11.008_bib0500","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/00001721-200204000-00003","article-title":"Activated protein C resistance in the absence of factor v leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications","volume":"13","author":"Zangari","year":"2002","journal-title":"Blood Coagul. Fibrinolysis"},{"issue":"4","key":"10.1016\/j.drudis.2019.11.008_bib0505","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1365-2141.2006.06208.x","article-title":"Acquired resistance to activated protein C (Aapcr) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism","volume":"134","author":"Elice","year":"2006","journal-title":"Br. J. Haematol."},{"issue":"3","key":"10.1016\/j.drudis.2019.11.008_bib0510","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1046\/j.1538-7836.2003.00083.x","article-title":"Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment","volume":"1","author":"Minnema","year":"2003","journal-title":"J. Thromb. Haemost."},{"issue":"5","key":"10.1016\/j.drudis.2019.11.008_bib0515","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1055\/s-2003-44554","article-title":"Hyperviscosity syndrome in plasma cell dyscrasias","volume":"29","author":"Mehta","year":"2003","journal-title":"Semin. Thromb. Hemost."},{"issue":"6","key":"10.1016\/j.drudis.2019.11.008_bib0520","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1586\/ehm.12.52","article-title":"Immunomodulator drug-based therapy in myeloma and the occurrence of thrombosis","volume":"5","author":"Boyle","year":"2012","journal-title":"Expert Rev. Hematol."},{"issue":"1","key":"10.1016\/j.drudis.2019.11.008_bib0525","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40959-017-0023-9","article-title":"Cardiac events during treatment with proteasome inhibitor therapy for multiple myeloma","volume":"3","author":"Chen","year":"2017","journal-title":"Cardio-oncology"},{"issue":"12","key":"10.1016\/j.drudis.2019.11.008_bib0530","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1080\/10428190701647887","article-title":"Prophylactic low-dose aspirin is effective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma","volume":"48","author":"Niesvizky","year":"2007","journal-title":"Leuk. Lymphoma"},{"issue":"1","key":"10.1016\/j.drudis.2019.11.008_bib0535","doi-asserted-by":"crossref","first-page":"S177","DOI":"10.1179\/102453312X13336169156933","article-title":"Thrombosis in multiple myeloma (MM)","volume":"17","author":"Cesarman-Maus","year":"2012","journal-title":"Hematology"},{"issue":"1","key":"10.1016\/j.drudis.2019.11.008_bib0540","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3390\/healthcare4010016","article-title":"Incidence and risk factors of thromboembolism with multiple myeloma in the presence of death as a competing risk: an empirical comparison of statistical methodologies","volume":"4","author":"Brown","year":"2016","journal-title":"Healthcare"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644619304465?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644619304465?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T12:44:28Z","timestamp":1761223468000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644619304465"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":108,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S1359644619304465"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2019.11.008","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New generation drugs for treatment of multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2019.11.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2019 Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}